We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

002074:SZSEGotion High-tech Co.,Ltd. Analysis

Data as of 2026-03-07 - not real-time

CN¥36.30

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Gotion High‑tech is trading at CNY 36.3, sitting just below its 20‑day SMA of 37.25 and well under the 50‑day SMA of 38.76, while the 30‑day volatility is elevated at 28 % and the computed beta is modest at 0.20. The RSI of 39.6 hints at a mildly oversold condition, yet the bearish MACD and a price hovering near the immediate support of CNY 35.65 suggest short‑term downside pressure.
On the fundamentals side, the company posted a robust 20.7 % revenue growth and a respectable ROE of 10.5 %, but its balance sheet is strained with a debt‑to‑equity ratio of 140 % and a negative free cash flow of -CNY 6.78 bn. Valuation metrics are mixed: the trailing PE of 19.6 is well below the industry average of 29.4, yet the DCF‑derived fair value of CNY 19.1 and a forward PE of 57.6 flag potential overvaluation. The dividend is modest at 0.28 % with a low payout ratio, but sustainability is questionable given cash flow constraints. Analyst consensus remains bullish with a median target of CNY 43.8, implying upside if the company can navigate its leverage and cash flow challenges.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish MACD and price below short‑term moving averages
  • Proximity to immediate support level
  • Elevated short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth but high debt load
  • Negative free cash flow limiting reinvestment
  • Valuation gap between trailing PE and industry average

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Long‑term tailwinds in EV and energy‑storage markets
  • Analyst buy consensus with upside target price
  • Solid ROE and competitive PE relative to peers

Key Metrics & Analysis

Financial Health

Revenue Growth20.70%
Profit Margin8.38%
P/E Ratio19.6
ROE10.49%
ROA0.86%
Debt/Equity140.64
P/B Ratio2.3
Op. Cash FlowCN¥2.9B
Free Cash FlowCN¥-6778478592
Industry P/E29.4

Technical Analysis

TrendNeutral
RSI39.6
SupportCN¥35.65
ResistanceCN¥38.62
MA 20CN¥37.25
MA 50CN¥38.76
MA 200CN¥36.04
MACDBearish
VolumeStable
Fear & Greed Index68.77

Valuation

Fair ValueCN¥19.10
Target PriceCN¥40.50
Upside/Downside11.57%
GradeOvervalued
TypeBlend
Dividend Yield0.28%

Risk Assessment

Beta0.20
Volatility28.23%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.